Table 3—

Effect of interventions on echocardiographic indices

PlaceboFenofibrateCoQCombinationP for interactionFenofibrate main effectPCoQ main effectP
n20161617
E′ (cm/s)
    Baseline8.4 ± 0.38.5 ± 0.39.2 ± 0.48.6 ± 0.4
    End8.6 ± 0.38.1 ± 0.38.9 ± 0.48.7 ± 0.40.094−0.1 ± 0.20.5390.1 ± 0.20.698
E/A
    Baseline0.82 ± 0.030.83 ± 0.030.90 ± 0.040.91 ± 0.10
    End0.83 ± 0.030.85 ± 0.030.92 ± 0.040.99 ± 0.110.2620.04 ± 0.020.1120.04 ± 0.020.129
DT (ms)
    Baseline218 ± 6233 ± 7215 ± 8215 ± 7
    End215 ± 6220 ± 9206 ± 7212 ± 60.3762 ± 60.779−2 ± 60.737
IVRT (ms)
    Baseline106 ± 3108 ± 1108 ± 2109 ± 2
    End108 ± 2112 ± 3109 ± 3111 ± 20.6552 ± 20.338−1 ± 20.530
Vp (cm/s)
    Baseline41.5 ± 1.442.0 ± 1.344.1 ± 2.041.9 ± 1.7
    End40.9 ± 1.244.4 ± 1.842.9 ± 1.742.9 ± 1.90.5312.4 ± 1.00.020−0.8 ± 1.00.451
E/E′
    Baseline7.7 ± 0.38.0 ± 0.47.8 ± 0.57.9 ± 0.5
    End7.6 ± 0.38.5 ± 0.38.3 ± 0.58.6 ± 0.50.3450.5 ± 0.30.0780.4 ± 0.30.130
E/Vp
    Baseline1.56 ± 0.071.60 ± 0.061.59 ± 0.051.60 ± 0.08
    End1.59 ± 0.061.56 ± 0.051.70 ± 0.071.73 ± 0.070.3670.00 ± 0.050.9400.12 ± 0.050.007
PV S/D
    Baseline1.55 ± 0.061.50 ± 0.061.41 ± 0.091.61 ± 0.13
    End1.60 ± 0.061.52 ± 0.071.43 ± 0.091.43 ± 0.080.933−0.06 ± 0.070.390−0.12 ± 0.070.081
PV ‘a’ rev (m/s)
    Baseline0.33 ± 0.010.33 ± 0.010.31 ± 0.010.33 ± 0.01
    End0.32 ± 0.010.32 ± 0.010.33 ± 0.010.34 ± 0.010.7850.00 ± 0.010.4570.02 ± 0.010.009
LVEF (%)
    Baseline63.2 ± 0.961.6 ± 1.064.6 ± 0.963.3 ± 1.2
    End64.1 ± 0.862.6 ± 1.264.6 ± 1.162.4 ± 0.80.6150.0 ± 0.80.9611.3 ± 0.80.102
S′ (cm/s)
    Baseline8.8 ± 0.29.4 ± 0.39.4 ± 0.38.7 ± 0.3
    End9.1 ± 0.29.3 ± 0.49.8 ± 0.48.6 ± 0.30.417−0.5 ± 0.30.0710.0 ± 0.30.914
LAV/BSA (ml/m2)
    Baseline30.4 ± 1.332.4 ± 1.831.3 ± 1.835.9 ± 2.5
    End32.4 ± 1.533.9 ± 1.831.7 ± 1.536.4 ± 2.60.6490.4 ± 1.00.693−1.0 ± 1.00.335
LVM/BSA (g/m2)
    Baseline92.5 ± 3.8101.5 ± 4.294.8 ± 3.590.1 ± 3.8
    End95.0 ± 4.0106.3 ± 4.595.1 ± 3.191.2 ± 4.20.5332.4 ± 1.80.195−3.5 ± 1.80.059
  • Data are means ± SEM. Main effect vs. placebo, adjusted for baseline and study site (general linear model). BSA, body surface area.